This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Prophylactic HIV drugs Market

Market Insights on Prophylactic HIV drugs covering sales outlook, demand forecast & up-to-date key trends

Prophylactic HIV Drugs Market by Drug Class, Distributional Channel & Region - Forecast 2022 – 2032

Prophylactic HIV Drugs Market Snapshot (2022-2032)

[250 Pages Report] The global prophylactic HIV drugs market size reached a valuation of around US$ 30 Bn in 2021. Further, with rising prevalence of HIV infection worldwide and growing awareness about HIV AIDS prevention, the demand for prophylactic HIV drugs is projected to register 4%CAGR between 2022 and 2032, totaling over US$ 40 Bn in 2028

Report Attribute

Details

Prophylactic HIV Drugs Market Size (2021)

US$ 30 Bn

Prophylactic HIV Drugs Market Estimated Growth Rate (2022-2032)

4%

Prophylactic HIV Drugs Market Projected Size (2028)

US$ 40 Bn

Over the years, human immunodeficiency virus (HIV) has become one of the leading causes of death worldwide affecting millions of people. The virus targets the immune system of infected patients and makes them vulnerable to many infections and cancers. 

Although there is no permanent cure available for HIV infection, the condition can be managed through increasing access to effective prevention, diagnosis, treatment, and care. Rising focus towards preventing acquisition of HIV is one of the major factors pushing the demand for prophylactic HIV drugs.

Prophylactic HIV drugs are advanced therapeutics used to prevent getting HIV infection in certain circumstances. They have especially effective in preventing acquisition of HIV from sex and injection drug use.

Amid rising prevalence of HIV, people across the world are showing a keen inclination towards consuming pre-exposure prophylaxis (PrEP) due to its better effectiveness. According to the Centers for Disease Control and Prevention (CDC), PrEP reduces the risk of getting HIV from sex and injection drug use by around 99% and 74% respectively.

Similarly, prophylactic HIV drugs such as antiretroviral (ARV) are gaining wider popularity due to their ability to prevent and control HIV infection.

Growing awareness among people regarding HIV and the benefits of prophylactic HIV drugs will continue to boost the sales of prophylactic HIV drugs during the forecast period.

Customize this Report

Let us know your requirement to get
100% FREE customization

Which are the Factors Stimulating Growth in Prophylactic HIV Drugs Market?

Rapid surge in HIV cases worldwide, continuous novel drug launches and approvals, and increasing need for preventing and controlling HIV are some of the major factors stimulating the growth of prophylactic HIV drugs market.

Prophylactic HIV drugs have become highly sought-after therapeutics for preventing the acquisition of HIV infection among people who are at a high risk. Consumption of these drugs significantly reduces the chances of HIV infection. They are mostly recommended during sex and injection drug use where there is a high chance of HIV transmission.

Growing popularity of prophylactic HIV drugs on account of their better effectiveness and cost-effective nature is providing a strong thrust to the growth of prophylactic HIV drugs market and the trend is likely to continue during the forecast period.

Similarly, increasing prevalence of HIV and its high mortality rate are pushing the demand for therapeutics like prophylactic HIV drugs. According to the World Health Organization (WHO), there were around 1.5 million newly infected cases of HIV and over 680000 deaths in 2020. This is prompting people to use prophylactic HIV drugs.

In addition to this, increasing government initiatives and investments in spreading awareness among people about HIV, its symptoms, precautions and treatment is expected to further expand the prophylactic HIV drugs market size during the forecast period.

What are the Challenges Faced by Prophylactic HIV Drugs Market?

Despite its optimistic stance, there are certain obstacles that are challenging the growth of prophylactic HIV drugs market. Some of these obstacles include side effects associated with prophylactic HIV drugs, strict government approval for these drugs, and low awareness levels about these therapeutics across low emerging economies.

It has been observed that prophylactic HIV drugs often lead to side effects such as headache, depression, nausea, vomiting, and abdominal pain, etc. As a result, many people refrain from consuming these therapeutics. This in turn is limiting the growth of prophylactic HIV drugs market.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Will North America Retain its Monopoly in the Global Prophylactic HIV Drugs Market?

According to Future Market Insights, North America is likely to retain its dominant position in the global prophylactic HIV drugs market, accounting for the largest market share through 2032. Growth in North America Prophylactic HIV drugs market is underpinned by presence of high level of awareness among people, surge in HIV infection cases, availability of advanced healthcare facilities, and growing adoption of new therapeutics.

Demand for prophylactic HIV drugs is especially rising across countries like the U.S. and Mexico due to surge in HIV cases. In recent years, there has been a rapid surge in cases of HIV infection in the U.S. due to rising incidence of unprotected sex and use of unsterile injections. According to the Centers for Disease Control and Prevention (CDC), there were around 34800 new HIV infection cases reported in the U.S. during 2019. This rise in HIV infection cases is playing a key role in pushing the growth of prophylactic HIV drugs market.

How Will Prophylactic HIV Drugs Market Fare in Europe?

Amid rising prevalence of HIV infection and increasing adoption of novel therapeutics, Europe prophylactic HIV drugs market is likely to grow at a considerable pace during the forecast period.

Over the last few decades, there has been a sharp rise in cases of HIV European countries like the U.K., Germany, and France due to various reasons. As per the European Centre for Disease Prevention and Control, over 2.2 million people have been diagnosed and reported with HIV in the WHO European Region during the last three decades. This in turn is fostering the growth of prophylactic HIV drugs market in the region.

Furthermore, presence of leading manufacturers such as ViiV Health is positively impacting the growth of prophylactic HIV drugs market across Europe.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Market Competition

Some of the leading manufacturers of prophylactic HIV drugs include Gilead Sciences, Inc, Merck Sharp & Dohme Corp., Merck & Co. Inc., Mylan NV, Cipla Inc., Genentech Inc., Bristol-Myers Squibb Company, and Johnson & Johnson Health Care Systems Inc.

These key players are rigorously investing in research and development to advance in HIV therapeutics. They have adopted strategies such as new product launches and approvals, mergers, partnerships, acquisitions, launching awareness campaigns, etc. to expand their customer bases as well as to gain an upper hand in the global prophylactic HIV drugs market. For instance, in December 2021, the U.S. Food and Drug Administration approved first injectable treatment “Apretude” for HIV pre-exposure prevention.

Report Scope

Report Attribute

Details

Growth Rate

CAGR of 4% from 2022 to 2032

Projected Market Valuation (2032)

US$ 40 Bn

Base Year for Estimation

2021

Historical Data

2015-2020

Forecast Period

2022-2032

Quantitative Units

Revenue in US$ Billion and CAGR from 2022-2032

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Drug Class
  • Distribution Channel
  • Region

Regions Covered

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • Middle East and Africa

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Argentina
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • ASEAN
  • GCC
  • South Africa

Key Companies Profiled

Customization

Available Upon Request

Key Segments Profiled in the Prophylactic HIV Drugs Industry Survey

By Drug Class:

  • Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI)
  • Integrase Inhibitor

By Distributional Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail Order Pharmacies
  • Drug Stores

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • Middle East and Africa

Frequently Asked Questions

FMI predicts the global prophylactic HIV drugs market to grow at a steady CAGR of around 4% throughout the forecast period.

North America is likely to account for the largest share of the global prophylactic HIV drugs market through 2032.

Gilead Sciences, Inc, Merck Sharp & Dohme Corp., Merck & Co. Inc., Mylan NV, Cipla Inc., Genentech Inc., and Bristol-Myers Squibb Company are some prominent prophylactic HIV drug manufacturers

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity 

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Product Life Cycle Analysis

    3.5. Supply Chain Analysis

        3.5.1. Supply Side Participants and their Roles

            3.5.1.1. Producers

            3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)

            3.5.1.3. Wholesalers and Distributors

        3.5.2. Value Added and Value Created at Node in the Supply Chain

        3.5.3. List of Raw Material Suppliers

        3.5.4. List of Existing and Potential Buyer’s

    3.6. Investment Feasibility Matrix

    3.7. Value Chain Analysis

        3.7.1. Profit Margin Analysis

        3.7.2. Wholesalers and Distributors

        3.7.3. Retailers

    3.8. PESTLE and Porter’s Analysis

    3.9. Regulatory Landscape

        3.9.1. By Key Regions

        3.9.2. By Key Countries

    3.10. Regional Parent Market Outlook

    3.11. Production and Consumption Statistics

    3.12. Import and Export Statistics

4. Global Prophylactic HIV drugs Market Analysis 2017-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Analysis, 2017-2021

    4.2. Current and Future Market Size Value (US$ Mn) & Volume (Tons) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Prophylactic HIV drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) & Volume (Tons) Analysis By Drug Class, 2017-2021

    5.3. Current and Future Market Size Value (US$ Mn) & Volume (Tons) Analysis and Forecast By Drug Class, 2022-2032

        5.3.1. Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI)

        5.3.2. Integrase Inhibitor

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017-2021

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2022-2032

6. Global Prophylactic HIV drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Distributional Channel

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) & Volume (Tons) Analysis By Distributional Channel, 2017-2021

    6.3. Current and Future Market Size Value (US$ Mn) & Volume (Tons) Analysis and Forecast By Distributional Channel, 2022-2032

        6.3.1. Hospital Pharmacies

        6.3.2. Retail Pharmacies

        6.3.3. Mail Order Pharmacies

        6.3.4. Drug Stores

    6.4. Y-o-Y Growth Trend Analysis By Distributional Channel, 2017-2021

    6.5. Absolute $ Opportunity Analysis By Distributional Channel, 2022-2032

7. Global Prophylactic HIV drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Mn) & Volume (Tons) Analysis By Region, 2017-2021

    7.3. Current Market Size Value (US$ Mn) & Volume (Tons) Analysis and Forecast By Region, 2022-2032

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. Asia Pacific

        7.3.5. MEA

    7.4. Market Attractiveness Analysis By Region

8. North America Prophylactic HIV drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    8.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017-2021

    8.2. Market Size Value (US$ Mn) & Volume (Tons) Forecast By Market Taxonomy, 2022-2032

        8.2.1. By Country

            8.2.1.1. U.S.

            8.2.1.2. Canada

        8.2.2. By Drug Class

        8.2.3. By Distributional Channel

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Drug Class

        8.3.3. By Distributional Channel

    8.4. Key Takeaways

9. Latin America Prophylactic HIV drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    9.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017-2021

    9.2. Market Size Value (US$ Mn) & Volume (Tons) Forecast By Market Taxonomy, 2022-2032

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Drug Class

        9.2.3. By Distributional Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By Distributional Channel

    9.4. Key Takeaways

10. Europe Prophylactic HIV drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017-2021

    10.2. Market Size Value (US$ Mn) & Volume (Tons) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. U.K.

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Drug Class

        10.2.3. By Distributional Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By Distributional Channel

    10.4. Key Takeaways

11. Asia Pacific Prophylactic HIV drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017-2021

    11.2. Market Size Value (US$ Mn) & Volume (Tons) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. China

            11.2.1.2. Japan

            11.2.1.3. South Korea

            11.2.1.4. Malaysia

            11.2.1.5. Singapore

            11.2.1.6. Australia

            11.2.1.7. New Zealand

            11.2.1.8. Rest of APAC

        11.2.2. By Drug Class

        11.2.3. By Distributional Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By Distributional Channel

    11.4. Key Takeaways

12. MEA Prophylactic HIV drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017-2021

    12.2. Market Size Value (US$ Mn) & Volume (Tons) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. GCC Countries

            12.2.1.2. South Africa

            12.2.1.3. Israel

            12.2.1.4. Rest of MEA

        12.2.2. By Drug Class

        12.2.3. By Distributional Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By Distributional Channel

    12.4. Key Takeaways

13. Key Countries Prophylactic HIV drugs Market Analysis

    13.1. U.S.

        13.1.1. Pricing Analysis

        13.1.2. Market Share Analysis, 2021

            13.1.2.1. By Drug Class

            13.1.2.2. By Distributional Channel

    13.2. Canada

        13.2.1. Pricing Analysis

        13.2.2. Market Share Analysis, 2021

            13.2.2.1. By Drug Class

            13.2.2.2. By Distributional Channel

    13.3. Brazil

        13.3.1. Pricing Analysis

        13.3.2. Market Share Analysis, 2021

            13.3.2.1. By Drug Class

            13.3.2.2. By Distributional Channel

    13.4. Mexico

        13.4.1. Pricing Analysis

        13.4.2. Market Share Analysis, 2021

            13.4.2.1. By Drug Class

            13.4.2.2. By Distributional Channel

    13.5. Germany

        13.5.1. Pricing Analysis

        13.5.2. Market Share Analysis, 2021

            13.5.2.1. By Drug Class

            13.5.2.2. By Distributional Channel

    13.6. U.K.

        13.6.1. Pricing Analysis

        13.6.2. Market Share Analysis, 2021

            13.6.2.1. By Drug Class

            13.6.2.2. By Distributional Channel

    13.7. France

        13.7.1. Pricing Analysis

        13.7.2. Market Share Analysis, 2021

            13.7.2.1. By Drug Class

            13.7.2.2. By Distributional Channel

    13.8. Spain

        13.8.1. Pricing Analysis

        13.8.2. Market Share Analysis, 2021

            13.8.2.1. By Drug Class

            13.8.2.2. By Distributional Channel

    13.9. Italy

        13.9.1. Pricing Analysis

        13.9.2. Market Share Analysis, 2021

            13.9.2.1. By Drug Class

            13.9.2.2. By Distributional Channel

    13.10. China

        13.10.1. Pricing Analysis

        13.10.2. Market Share Analysis, 2021

            13.10.2.1. By Drug Class

            13.10.2.2. By Distributional Channel

    13.11. Japan

        13.11.1. Pricing Analysis

        13.11.2. Market Share Analysis, 2021

            13.11.2.1. By Drug Class

            13.11.2.2. By Distributional Channel

    13.12. South Korea

        13.12.1. Pricing Analysis

        13.12.2. Market Share Analysis, 2021

            13.12.2.1. By Drug Class

            13.12.2.2. By Distributional Channel

    13.13. Malaysia

        13.13.1. Pricing Analysis

        13.13.2. Market Share Analysis, 2021

            13.13.2.1. By Drug Class

            13.13.2.2. By Distributional Channel

    13.14. Singapore

        13.14.1. Pricing Analysis

        13.14.2. Market Share Analysis, 2021

            13.14.2.1. By Drug Class

            13.14.2.2. By Distributional Channel

    13.15. Australia

        13.15.1. Pricing Analysis

        13.15.2. Market Share Analysis, 2021

            13.15.2.1. By Drug Class

            13.15.2.2. By Distributional Channel

    13.16. New Zealand

        13.16.1. Pricing Analysis

        13.16.2. Market Share Analysis, 2021

            13.16.2.1. By Drug Class

            13.16.2.2. By Distributional Channel

    13.17. GCC Countries

        13.17.1. Pricing Analysis

        13.17.2. Market Share Analysis, 2021

            13.17.2.1. By Drug Class

            13.17.2.2. By Distributional Channel

    13.18. South Africa

        13.18.1. Pricing Analysis

        13.18.2. Market Share Analysis, 2021

            13.18.2.1. By Drug Class

            13.18.2.2. By Distributional Channel

    13.19. Israel

        13.19.1. Pricing Analysis

        13.19.2. Market Share Analysis, 2021

            13.19.2.1. By Drug Class

            13.19.2.2. By Distributional Channel

14. Market Structure Analysis

    14.1. Competition Dashboard

    14.2. Competition Benchmarking

    14.3. Market Share Analysis of Top Players

        14.3.1. By Regional

        14.3.2. By Drug Class

        14.3.3. By Distributional Channel

15. Competition Analysis

    15.1. Competition Deep Dive

        15.1.1. Gilead Sciences

            15.1.1.1. Overview

            15.1.1.2. Product Portfolio

            15.1.1.3. Profitability by Market Segments

            15.1.1.4. Sales Footprint

            15.1.1.5. Strategy Overview

                15.1.1.5.1. Marketing Strategy

                15.1.1.5.2. Product Strategy

                15.1.1.5.3. Channel Strategy

        15.1.2. Merck Sharp & Dohme Corp.

            15.1.2.1. Overview

            15.1.2.2. Product Portfolio

            15.1.2.3. Profitability by Market Segments

            15.1.2.4. Sales Footprint

            15.1.2.5. Strategy Overview

                15.1.2.5.1. Marketing Strategy

                15.1.2.5.2. Product Strategy

                15.1.2.5.3. Channel Strategy

        15.1.3. AbbVie

            15.1.3.1. Overview

            15.1.3.2. Product Portfolio

            15.1.3.3. Profitability by Market Segments

            15.1.3.4. Sales Footprint

            15.1.3.5. Strategy Overview

                15.1.3.5.1. Marketing Strategy

                15.1.3.5.2. Product Strategy

                15.1.3.5.3. Channel Strategy

        15.1.4. APOTEX INC.

            15.1.4.1. Overview

            15.1.4.2. Product Portfolio

            15.1.4.3. Profitability by Market Segments

            15.1.4.4. Sales Footprint

            15.1.4.5. Strategy Overview

                15.1.4.5.1. Marketing Strategy

                15.1.4.5.2. Product Strategy

                15.1.4.5.3. Channel Strategy

        15.1.5. Auro Pharma Inc.

            15.1.5.1. Overview

            15.1.5.2. Product Portfolio

            15.1.5.3. Profitability by Market Segments

            15.1.5.4. Sales Footprint

            15.1.5.5. Strategy Overview

                15.1.5.5.1. Marketing Strategy

                15.1.5.5.2. Product Strategy

                15.1.5.5.3. Channel Strategy

        15.1.6. Boehringer Ingelheim International GmbH

            15.1.6.1. Overview

            15.1.6.2. Product Portfolio

            15.1.6.3. Profitability by Market Segments

            15.1.6.4. Sales Footprint

            15.1.6.5. Strategy Overview

                15.1.6.5.1. Marketing Strategy

                15.1.6.5.2. Product Strategy

                15.1.6.5.3. Channel Strategy

        15.1.7. Bristol-Myers Squibb Company

            15.1.7.1. Overview

            15.1.7.2. Product Portfolio

            15.1.7.3. Profitability by Market Segments

            15.1.7.4. Sales Footprint

            15.1.7.5. Strategy Overview

                15.1.7.5.1. Marketing Strategy

                15.1.7.5.2. Product Strategy

                15.1.7.5.3. Channel Strategy

        15.1.8. Cipla Inc.

            15.1.8.1. Overview

            15.1.8.2. Product Portfolio

            15.1.8.3. Profitability by Market Segments

            15.1.8.4. Sales Footprint

            15.1.8.5. Strategy Overview

                15.1.8.5.1. Marketing Strategy

                15.1.8.5.2. Product Strategy

                15.1.8.5.3. Channel Strategy

        15.1.9. GalaxoSmithKline PLC

            15.1.9.1. Overview

            15.1.9.2. Product Portfolio

            15.1.9.3. Profitability by Market Segments

            15.1.9.4. Sales Footprint

            15.1.9.5. Strategy Overview

                15.1.9.5.1. Marketing Strategy

                15.1.9.5.2. Product Strategy

                15.1.9.5.3. Channel Strategy

        15.1.10. Genentech Inc.

            15.1.10.1. Overview

            15.1.10.2. Product Portfolio

            15.1.10.3. Profitability by Market Segments

            15.1.10.4. Sales Footprint

            15.1.10.5. Strategy Overview

                15.1.10.5.1. Marketing Strategy

                15.1.10.5.2. Product Strategy

                15.1.10.5.3. Channel Strategy

        15.1.11. Mylan NV

            15.1.11.1. Overview

            15.1.11.2. Product Portfolio

            15.1.11.3. Profitability by Market Segments

            15.1.11.4. Sales Footprint

            15.1.11.5. Strategy Overview

                15.1.11.5.1. Marketing Strategy

                15.1.11.5.2. Product Strategy

                15.1.11.5.3. Channel Strategy

        15.1.12. Pfizer Inc.

            15.1.12.1. Overview

            15.1.12.2. Product Portfolio

            15.1.12.3. Profitability by Market Segments

            15.1.12.4. Sales Footprint

            15.1.12.5. Strategy Overview

                15.1.12.5.1. Marketing Strategy

                15.1.12.5.2. Product Strategy

                15.1.12.5.3. Channel Strategy

        15.1.13. Teva Pharmaceutical Industries Ltd

            15.1.13.1. Overview

            15.1.13.2. Product Portfolio

            15.1.13.3. Profitability by Market Segments

            15.1.13.4. Sales Footprint

            15.1.13.5. Strategy Overview

                15.1.13.5.1. Marketing Strategy

                15.1.13.5.2. Product Strategy

                15.1.13.5.3. Channel Strategy

16. Assumptions & Acronyms Used

17. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Region, 2017-2032

Table 2: Global Prophylactic HIV drugs Market Volume (Tons) Forecast by Region, 2017-2032

Table 3: Global Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 4: Global Prophylactic HIV drugs Market Volume (Tons) Forecast by Drug Class, 2017-2032

Table 5: Global Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032

Table 6: Global Prophylactic HIV drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032

Table 7: North America Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 8: North America Prophylactic HIV drugs Market Volume (Tons) Forecast by Country, 2017-2032

Table 9: North America Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 10: North America Prophylactic HIV drugs Market Volume (Tons) Forecast by Drug Class, 2017-2032

Table 11: North America Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032

Table 12: North America Prophylactic HIV drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032

Table 13: Latin America Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 14: Latin America Prophylactic HIV drugs Market Volume (Tons) Forecast by Country, 2017-2032

Table 15: Latin America Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 16: Latin America Prophylactic HIV drugs Market Volume (Tons) Forecast by Drug Class, 2017-2032

Table 17: Latin America Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032

Table 18: Latin America Prophylactic HIV drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032

Table 19: Europe Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 20: Europe Prophylactic HIV drugs Market Volume (Tons) Forecast by Country, 2017-2032

Table 21: Europe Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 22: Europe Prophylactic HIV drugs Market Volume (Tons) Forecast by Drug Class, 2017-2032

Table 23: Europe Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032

Table 24: Europe Prophylactic HIV drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032

Table 25: Asia Pacific Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 26: Asia Pacific Prophylactic HIV drugs Market Volume (Tons) Forecast by Country, 2017-2032

Table 27: Asia Pacific Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 28: Asia Pacific Prophylactic HIV drugs Market Volume (Tons) Forecast by Drug Class, 2017-2032

Table 29: Asia Pacific Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032

Table 30: Asia Pacific Prophylactic HIV drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032

Table 31: MEA Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Country, 2017-2032

Table 32: MEA Prophylactic HIV drugs Market Volume (Tons) Forecast by Country, 2017-2032

Table 33: MEA Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Drug Class, 2017-2032

Table 34: MEA Prophylactic HIV drugs Market Volume (Tons) Forecast by Drug Class, 2017-2032

Table 35: MEA Prophylactic HIV drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032

Table 36: MEA Prophylactic HIV drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Prophylactic HIV drugs Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 2: Global Prophylactic HIV drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032

Figure 3: Global Prophylactic HIV drugs Market Value (US$ Mn) by Region, 2022-2032

Figure 4: Global Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Region, 2017-2032

Figure 5: Global Prophylactic HIV drugs Market Volume (Tons) Analysis by Region, 2017-2032

Figure 6: Global Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 7: Global Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 8: Global Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 9: Global Prophylactic HIV drugs Market Volume (Tons) Analysis by Drug Class, 2017-2032

Figure 10: Global Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 11: Global Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 12: Global Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032

Figure 13: Global Prophylactic HIV drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032

Figure 14: Global Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032

Figure 15: Global Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032

Figure 16: Global Prophylactic HIV drugs Market Attractiveness by Drug Class, 2022-2032

Figure 17: Global Prophylactic HIV drugs Market Attractiveness by Distributional Channel, 2022-2032

Figure 18: Global Prophylactic HIV drugs Market Attractiveness by Region, 2022-2032

Figure 19: North America Prophylactic HIV drugs Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 20: North America Prophylactic HIV drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032

Figure 21: North America Prophylactic HIV drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 22: North America Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 23: North America Prophylactic HIV drugs Market Volume (Tons) Analysis by Country, 2017-2032

Figure 24: North America Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 25: North America Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 26: North America Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 27: North America Prophylactic HIV drugs Market Volume (Tons) Analysis by Drug Class, 2017-2032

Figure 28: North America Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 29: North America Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 30: North America Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032

Figure 31: North America Prophylactic HIV drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032

Figure 32: North America Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032

Figure 33: North America Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032

Figure 34: North America Prophylactic HIV drugs Market Attractiveness by Drug Class, 2022-2032

Figure 35: North America Prophylactic HIV drugs Market Attractiveness by Distributional Channel, 2022-2032

Figure 36: North America Prophylactic HIV drugs Market Attractiveness by Country, 2022-2032

Figure 37: Latin America Prophylactic HIV drugs Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 38: Latin America Prophylactic HIV drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032

Figure 39: Latin America Prophylactic HIV drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 40: Latin America Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 41: Latin America Prophylactic HIV drugs Market Volume (Tons) Analysis by Country, 2017-2032

Figure 42: Latin America Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 43: Latin America Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 44: Latin America Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 45: Latin America Prophylactic HIV drugs Market Volume (Tons) Analysis by Drug Class, 2017-2032

Figure 46: Latin America Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 47: Latin America Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 48: Latin America Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032

Figure 49: Latin America Prophylactic HIV drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032

Figure 50: Latin America Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032

Figure 51: Latin America Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032

Figure 52: Latin America Prophylactic HIV drugs Market Attractiveness by Drug Class, 2022-2032

Figure 53: Latin America Prophylactic HIV drugs Market Attractiveness by Distributional Channel, 2022-2032

Figure 54: Latin America Prophylactic HIV drugs Market Attractiveness by Country, 2022-2032

Figure 55: Europe Prophylactic HIV drugs Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 56: Europe Prophylactic HIV drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032

Figure 57: Europe Prophylactic HIV drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 58: Europe Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 59: Europe Prophylactic HIV drugs Market Volume (Tons) Analysis by Country, 2017-2032

Figure 60: Europe Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 61: Europe Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 62: Europe Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 63: Europe Prophylactic HIV drugs Market Volume (Tons) Analysis by Drug Class, 2017-2032

Figure 64: Europe Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 65: Europe Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 66: Europe Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032

Figure 67: Europe Prophylactic HIV drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032

Figure 68: Europe Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032

Figure 69: Europe Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032

Figure 70: Europe Prophylactic HIV drugs Market Attractiveness by Drug Class, 2022-2032

Figure 71: Europe Prophylactic HIV drugs Market Attractiveness by Distributional Channel, 2022-2032

Figure 72: Europe Prophylactic HIV drugs Market Attractiveness by Country, 2022-2032

Figure 73: Asia Pacific Prophylactic HIV drugs Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 74: Asia Pacific Prophylactic HIV drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032

Figure 75: Asia Pacific Prophylactic HIV drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 76: Asia Pacific Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 77: Asia Pacific Prophylactic HIV drugs Market Volume (Tons) Analysis by Country, 2017-2032

Figure 78: Asia Pacific Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 79: Asia Pacific Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 80: Asia Pacific Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 81: Asia Pacific Prophylactic HIV drugs Market Volume (Tons) Analysis by Drug Class, 2017-2032

Figure 82: Asia Pacific Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 83: Asia Pacific Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 84: Asia Pacific Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032

Figure 85: Asia Pacific Prophylactic HIV drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032

Figure 86: Asia Pacific Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032

Figure 87: Asia Pacific Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032

Figure 88: Asia Pacific Prophylactic HIV drugs Market Attractiveness by Drug Class, 2022-2032

Figure 89: Asia Pacific Prophylactic HIV drugs Market Attractiveness by Distributional Channel, 2022-2032

Figure 90: Asia Pacific Prophylactic HIV drugs Market Attractiveness by Country, 2022-2032

Figure 91: MEA Prophylactic HIV drugs Market Value (US$ Mn) by Drug Class, 2022-2032

Figure 92: MEA Prophylactic HIV drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032

Figure 93: MEA Prophylactic HIV drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 94: MEA Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Country, 2017-2032

Figure 95: MEA Prophylactic HIV drugs Market Volume (Tons) Analysis by Country, 2017-2032

Figure 96: MEA Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 97: MEA Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 98: MEA Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Drug Class, 2017-2032

Figure 99: MEA Prophylactic HIV drugs Market Volume (Tons) Analysis by Drug Class, 2017-2032

Figure 100: MEA Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Drug Class, 2022-2032

Figure 101: MEA Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Drug Class, 2022-2032

Figure 102: MEA Prophylactic HIV drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032

Figure 103: MEA Prophylactic HIV drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032

Figure 104: MEA Prophylactic HIV drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032

Figure 105: MEA Prophylactic HIV drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032

Figure 106: MEA Prophylactic HIV drugs Market Attractiveness by Drug Class, 2022-2032

Figure 107: MEA Prophylactic HIV drugs Market Attractiveness by Distributional Channel, 2022-2032

Figure 108: MEA Prophylactic HIV drugs Market Attractiveness by Country, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

HIV Antivirals Market

Published : June 2022

Healthcare

HIV Diagnostics Market

Published : May 2022

Healthcare

Infection Prevention Market

Published : September 2021

Healthcare

HIV/HBV/HCV Test Kits Market

Published : February 2022

Google translate

Prophylactic HIV drugs Market